Science Corporation, a neurotechnology startup developing brain computer interface (BCI) implants to restore vision in blind individuals, has secured $230 million in a Series B funding round. The capital will accelerate clinical trials, manufacturing scale up, and regulatory progress for its high-resolution cortical visual prosthesis, which bypasses damaged eyes and optic nerves by directly stimulating the visual cortex offering a potential breakthrough for patients with conditions such as retinitis pigmentosa, optic nerve damage, and cortical blindness.
Glimpse:
The $230 million round, announced on January 28, 2026, was led by a consortium of top tier investors including ARCH Venture Partners, Prime Movers Lab, and Khosla Ventures, with participation from new strategic partners. Science Corporation’s BCI implant uses thousands of microelectrodes to deliver precise visual information patterns to the brain, enabling perception of shapes, motion, and basic object recognition. The funding will support expanded first in human trials (currently underway), device miniaturisation, long-term safety studies, and preparation for pivotal trials aimed at FDA and global regulatory approval.
Science Corporation has raised $230 million in a Series B financing round to propel its brain computer interface (BCI) implant technology toward restoring functional vision in people who are blind due to retinal or optic nerve damage. The oversubscribed round, closed in late January 2026, brings the company’s total funding to over $350 million and reflects strong investor belief in the potential of cortical visual prostheses to address one of the most challenging forms of blindness.
Unlike retinal implants (which require intact optic nerves), Science Corporation’s device targets the visual cortex directly, bypassing damage to the eye or optic pathway. The implant consists of a small array of ultra-thin, flexible microelectrodes inserted onto the surface of the brain’s visual cortex. External glasses equipped with a camera capture visual scenes, process them into stimulation patterns, and wirelessly transmit signals to the implant creating phosphene based perceptions (spots of light) that the brain learns to interpret as basic shapes, motion, and object outlines.
Early feasibility studies have shown participants achieving object localisation, motion detection, and simple form recognition, with ongoing refinements improving resolution and training protocols. The company is now advancing first in human trials in the U.S. and select international sites, focusing on safety, device longevity, and perceptual quality.
Science Corporation CEO stated: “Blindness from retinal or optic nerve damage has been untreatable for most patients. Our cortical BCI approach offers a fundamentally new path to vision restoration one that doesn’t depend on the health of the eye. This funding allows us to move quickly through clinical development and bring this technology to the people who need it most.”
The round was led by ARCH Venture Partners, with significant participation from Prime Movers Lab, Khosla Ventures, and new strategic investors. Proceeds will support:
- Expanded clinical trials (including larger cohorts and longer follow-up)
- Miniaturisation and wireless power improvements
- Manufacturing scale-up for GMP-compliant devices
- Regulatory engagement with FDA and international bodies
- Long-term neuroplasticity and training studies
The announcement aligns with growing momentum in BCI therapeutics, following high-profile advancements in motor and speech restoration. Science Corporation’s focus on vision restoration positions it as a leader in sensory BCI applications, with potential future extensions to other sensory modalities.
“For millions of people living with untreatable blindness, this isn’t just technology it’s the possibility of seeing again. We’re building the bridge between brain and world, one pixel at a time.”
By
HB Team
Related News
